I actually never liked him and am happy to see him go.
The guy was far too loose with his words, over optimistic and skating the line looked unprofessional as a CEO with an opportunity this positive.
The recent meeting with Amylyx was a red-flag for me, rubbing shoulders and then praising them after such a failure, most likely spilling far too much information and making us an easy takeover target. Its as almost like he was throwing blood into the water for the sharks to circle.
Rushing and pumping, as we have seen in other biotech's is not a fruitful strategy as a CEO.
Id much prefer the style of an Alan Taylor or Daniel Tillet.
Ann: Resignation of Dr Michael Thurn & appointment of John Clark, page-47
-
- There are more pages in this discussion • 215 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $91.22M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 21.5¢ | 20.5¢ | $174.5K | 841.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 458470 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 144453 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |